Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity

Pharmaceuticals

Volumn 7, Issue 10, 2014, Pages 990-998

  Gupta, Ajay ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Rockwell Medical   (United States)

Author keywords

Aluminum toxicity; CKD; Ferric citrate

Indexed keywords

ALUMINUM; DRINKING WATER; FERRIC CITRATE; FERRIC CITRATE HYDRATE; PHOSPHATE BINDING AGENT; PLACEBO; TAP WATER; UNCLASSIFIED DRUG;

ALUMINUM OVERLOAD; CHRONIC KIDNEY DISEASE; DRUG APPROVAL; DRUG MECHANISM; FOOD; HUMAN; HYPERPHOSPHATEMIA; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; NONHUMAN; NOTE; RISK REDUCTION; SOLUBILIZATION; TIGHT JUNCTION; URINARY EXCRETION;

EID: 84908164058     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph7100990     Document Type: Note

References (30)

1. Yokoyama, K.; Hirakata, H.; Akiba, T.; Fukagawa, M.; Nakayama, M.; Sawada, K.; Kumagai, Y.; Block, G.A. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent ckd. Clin. J. Am. Soc. Nephrol. 2014, 9, 543-552.
2. Yokoyama, K.; Akiba, T.; Fukagawa, M.; Nakayama, M.; Sawada, K.; Kumagai, Y.; Chertow, G.M.; Hirakata, H. A randomized trial of jtt-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol. Dial. Transplant. 2014, 29, 1053-1060.
3. Nolan, C.R.; DeGoes, J.J.; Alfrey, A.C. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South. Med. J. 1994, 87, 894-898.
4. Guidelines for Drinking-Water Quality; World Health Organization: Geneva, Switzerland, 2004.
5. Pennington, J.A. Aluminium content of foods and diets. Food Addit. Contam. 1988, 5, 161-232.
6. Greger, J.L. Aluminum content of the american diet. Food Technol. 1985, 39, 73-80.
7. Rajwanshi, P.; Singh, V.; Gupta, M.K.; Kumari, V.; Shrivastav, R.; Ramanamurthy, M.; Dass, S. Studies on aluminium leaching from cookware in tea and coffee and estimation of aluminium content in toothpaste, baking powder and paan masala. Sci. Total Environ. 1997, 193, 243-249.
8. Koch, K.R.; Pougnet, M.A.; de Villiers, S.; Monteagudo, F. Increased urinary excretion of al after drinking tea. Nature 1988, 333, 122.
9. Aluminium in Drinking-Water: Background Document for Development of Who Guidelines for Drinking-Water Quality; World Health Organization: Geneva, Switzerland, 2003; pp. 1-14.
10. Lione, A. The prophylactic reduction of aluminium intake. Food Chem. Toxicol. 1983, 21, 103-109.
11. Partridge, N.A.; Regnier, F.E.; White, J.L.; Hem, S.L. Influence of dietary constituents on intestinal absorption of aluminum. Kidney Int. 1989, 35, 1413-1417.
12. Krewski, D.; Yokel, R.A.; Nieboer, E.; Borchelt, D.; Cohen, J.; Harry, J.; Kacew, S.; Lindsay, J.; Mahfouz, A.M.; Rondeau, V. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J. Toxicol Environ. Health B Crit Rev. 2007, 10 (Suppl. 1), 1-269.
13. Parkinson, I.S.; Ward, M.K.; Kerr, D.N. Dialysis encephalopathy, bone disease and anaemia: The aluminum intoxication syndrome during regular haemodialysis. J. Clin. Pathol. 1981, 34, 1285-1294.
14. Foley, C.M.; Polinsky, M.S.; Gruskin, A.B.; Baluarte, H.J.; Grover, W.D. Encephalopathy in infants and children with chronic renal disease. Arch. Neurol. 1981, 38, 656-658.
15. Froment, D.H.; Buddington, B.; Miller, N.L.; Alfrey, A.C. Effect of solubility on the gastrointestinal absorption of aluminum from various aluminum compounds in the rat. J. Lab. Clin. Med. 1989, 114, 237-242.
16. Froment, D.P.; Molitoris, B.A.; Buddington, B.; Miller, N.; Alfrey, A.C. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int. 1989, 36, 978-984.
17. Slanina, P.; Falkeborn, Y.; Frech, W.; Cedergren, A. Aluminium concentrations in the brain and bone of rats fed citric acid, aluminium citrate or aluminium hydroxide. Food Chem. Toxicol. 1984, 22, 391-397.
18. Alfrey, A.C. Aluminum. Adv. Clin. Chem. 1983, 23, 69-91.
19. Kausz, A.T.; Antonsen, J.E.; Hercz, G.; Pei, Y.; Weiss, N.S.; Emerson, S.; Sherrard, D.J. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am. J. Kidney Dis. 1999, 34, 688-693.
20. Pei, Y.; Hercz, G.; Greenwood, C.; Sherrard, D.; Segre, G.; Manuel, A.; Saiphoo, C.; Fenton, S. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int. 1992, 41, 1374-1382.
21. Van Landeghem, G.F.; D’Haese, P.C.; Lamberts, L.V.; Djukanovic, L.; Pejanovic, S.; Goodman, W.G.; De Broe, M.E. Low serum aluminum values in dialysis patients with increased bone aluminum levels. Clin. Nephrol. 1998, 50, 69-76.
22. D’Haese, P.C.; Couttenye, M.M.; De Broe, M.E. Diagnosis and treatment of aluminium bone disease. Nephrol Dial. Transplant. 1996, 1 (Suppl. 3), 74-79.
23. Malluche, H.H. Aluminium and bone disease in chronic renal failure. Nephrol. Dial. Transplant. 2002, 17 (Suppl. 2), 21-24.
24. D’Haese, P.C.; Couttenye, M.M.; Goodman, W.G.; Lemoniatou, E.; Digenis, P.; Sotornik, I.; Fagalde, A.; Barsoum, R.S.; Lamberts, L.V.; De Broe, M.E. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol. Dial. Transplant. 1995, 10, 1874-1884.
25. Heinrich, H.C. Intestinal absorption of 59fe from neutron-activated commercial oral iron(iii)-citrate and iron(iii)-hydroxide-polymaltose complexes in man. Arzneimittelforschung 1987, 37, 105-107.
26. Yang, W.C.; Yang, C.S.; Hou, C.C.; Wu, T.H.; Young, E.W.; Hsu, C.H. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol. Dial. Transplant. 2002, 17, 265-270.
27. Perez, G.; Pregi, N.; Vittori, D.; Di Risio, C.; Garbossa, G.; Nesse, A. Aluminum exposure affects transferrin-dependent and -independent iron uptake by k562 cells. Biochim. Biophys. Acta 2005, 1745, 124-130.
28. Ward, R.J.; Zhang, Y.; Crichton, R.R. Aluminium toxicity and iron homeostasis. J. Inorg. Biochem. 2001, 87, 9-14.
29. Wu, Z.; Du, Y.; Xue, H.; Wu, Y.; Zhou, B. Aluminum induces neurodegeneration and its toxicity arises from increased iron accumulation and reactive oxygen species (ros) production. Neurobiol. Aging 2012, 33, 199 e191-112.
30. Kawahara, M.; Kato-Negishi, M. Link between aluminum and the pathogenesis of alzheimer’s disease: The integration of the aluminum and amyloid cascade hypotheses. Int. J. Alzheimers Dis. 2011, 2011, 276393.